US › Healthcare

Alx Oncology Holdings  (ALXO)

US · Healthcare · Biotechnology

$1.97+2.07%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-17.9M
Profit YoY
+41.7%
EPS
$-0.17
EPS estimate
$-0.15

EPS came in at -0.17 against a street estimate of -0.15 — a miss of 13.3%.

Key statistics

Market cap
$259.7M
Forward P/E
0.0
P/B
1.73
Book value
$1.12
EPS (TTM)
$-1.49
52-week high
$2.66
52-week low
$0.60
50-day MA
$1.88
200-day MA
$1.76
Beta
0.40

Analyst view

Analysts rate Alx Oncology Holdings  a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $4.60.

Shareholding

Insiders
0.92%
Institutions
78.88%

Largest institutional holders

FundStake
RA Capital Management, LLC9.67%
TCG Crossover Management, LLC9.67%
venBio Partners LLC9.58%
Redmile Group, LLC5.92%
Blackstone Inc4.33%
Driehaus Capital Management LLC4.26%
Vanguard Capital Management, LLC3.11%
Marshall Wace Asset Management Ltd2.79%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Alx Oncology Holdings  — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.